Possible applications of rac-hopantenic acid in the treatment of cognitive, anxiety and depressive disorders in patients with essential arterial hypertension

Ostroumova O.D.

doi:https://doi.org/10.17116/jnevro2018118101115

Close metadata

Recommended articles:

The main mechanisms of development of cognitive impairment. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):13-18

Cognitive impairment in patients with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73

Cognitive impairment after major surgical operations. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):74-80

Analysis of cognitive status in patients with different nosologies and clinical variants of very late manifesting schizophreniform psychosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):88-93

Depression Anxiety Stress Scale (russian language version). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):103-107

Investigation of the relationship of individual characteristics of the brain bioelectrical activity with levels of mental stress, aggression, anxiety, and depression. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):108-117

Prevalence and characteristics of risk factors for cerebrovascular disease in overweight. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):118-124

Gender differences in vertebrobasilar hemodynamics in response to manual-physical impact in the treatment of essential arterial hypertension using the method of A.Yu. Shishonin. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):5-10

Dynamics of amplitude electrocardiographic criteria of left ventricular hypertrophy in response to manual-physical effects on the cervical spine using the method of A.Yu. Shishonin. Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(2):21-25

Conscious sedation with benzodiazepines in pediatric outpatient dentistry. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):55-63

Abstract:

Essential arterial hypertension (AH) is one of the main risk factors for the development of cognitive impairment and dementia. Cognitive decline is an early sign of brain damage as a target organ of hypertension, it occurs even in patients with uncomplicated hypertension with minimal duration of disease. Cognitive impairment progresses with increasing age and hypertension duration, as well as in non-controlled AH. In patients with hypertension, the prevalence of emotional disorders — anxiety and depression is also high. In addition to antihypertensive therapy, hypertensive patients need correction of concomitant cognitive and emotional disorders. Rat-gopantenic acid simultaneously corrects both emotional and cognitive impairment, and has a good tolerability profile as well. An analysis of the evidence base of rac-gopantenic acid showed its high efficacy in the treatment of mental disorders and good tolerability along with a positive effect on somatic disorders and results of antihypertensive therapy. Taken together, they enhance adherence to treatment and, consequently, reduce the cardiovascular risk.

Keywords:

essential arterial hypertension

cognitive impairment

anxiety

rac-gopantenic acid

D-

L-gopantenic acid

pantogam active

Authors:

Ostroumova O.D.

Kafedra fakul'tetskoĭ terapii i professional'nykh bolezneĭ Moskovskogo gosudarstvennogo mediko-stomatologicheskogo universiteta im. A.I. Evdokimova, Moskva

SPIN RSCI: 3910-6585
Scopus AuthorID: 7004067629
ResearcherID: M-9553-2014
ORCID: 0000-0002-0795-8225

Close metadata

References:

Wortmann M. Dementia: a global health priority — highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012;4:40. https://doi.org/10.1186/alzrt143
Wu YT, Fratiglioni L, Matthews FE, Lobo A, Breteler MM, Skoog I, Brayne C. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15:116-124. https://doi.org/10.1016/S1474-4422(15)00092-7
Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, Launer LJ, Laurent S, Lopez OL, Nyenhuis D, Petersen RC, Schneider JA, Tzourio C, Arnett DK, Bennett DA, Chui HC, Higashida RT, Lindquist R, Nilsson PM, Roman GC, Sellke FW, Seshadri S.; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42:2672-2713. https://doi.org/10.1161/STR.0b013e3182299496
Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology. 2000;54:4-9.
Ganguli M. Epidemiology of dementia. Chapt 38. Principles and Practice of Geriatric Psychiatry. Abou-Saleh MT, Katona C, Kumar A. eds. 3rd ed. Hoboken, NJ: Wiley; 2011.
Satizabal CL, Beiser AS, Chouraki V, Chêne G, Dufouil C, Seshadri S. Incidence of dementia over three decades in the Framingham Heart Study. N Engl J Med. 2016;374:523-532. https://doi.org/10.1056/NEJMoa1504327
Yang Z, Lin PJ, Levey A. Monetary costs of dementia in the United States. N Engl J Med. 2013;369:489. https://doi.org/10.1056/NEJMc1305541#SA1
Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000;54:447-451.
Hachinski V. Preventable senility: a call for action against the vascular dementias. Lancet. 1992;340:645-648.
Moorhouse P, Rockwood K. Vascular cognitive impairment: current concepts and clinical developments. Lancet Neurol. 2008;7:246-255. https://doi.org/10.1016/S1474-4422(08)70040-1
Dichgans M, Zietemann V. Prevention of vascular cognitive impairment. Stroke. 2012;43:3137-3146. https://doi.org/10.1161/STROKEAHA.112.651778
Chazova IE, Ratova LG, Boytsov SA, Nebieridze DV. Diagnosis and treatment of arterial hypertension. Sistemnye Gipertenzii. 2010;3:5-26. (In Russ.)
Shal’nova SA, Balanova YuA, Konstantinov VV, Timofeeva TN, Ivanov VM, Kapustina AV, Deev AD. Arterial hypertension: prevalence, awareness, intake of antihypertensive drugs and the effectiveness of treatment among the population of the Russian Federation. Rossijskij Kardiologicheskij Zhurnal. 2006;11(4):45-50. (In Russ.)
Obisesan TO, Obisesan OA, Martins S, Alamgir L, Bond V, Maxwell C, Gillum RF. High blood pressure, hypertension, and high pulse pressure are associated with poorer cognitive function in persons aged 60 and older: the Third National Health and Nutrition Examination Survey. J Am Geriatr Soc. 2008;56:501-509. https://doi.org/10.1111/j.1532-5415.2007.01592.x
Kuo HK, Sorond F, Iloputaife I, Gagnon M, Milberg W, Lipsitz LA. Effect of blood pressure on cognitive functions in elderly persons. J Gerontol A Biol Sci Med Sci. 2004;59:1191-1194. PMID:15602074. PMCID:PMC4418553.
Waldstein SR, Giggey PP, Thayer JF, Zonderman AB. Nonlinear relations of blood pressure to cognitive function: the Baltimore Longitudinal Study of Aging. Hypertension. 2005;45:374-379. https://doi.org/10.1161/01.HYP.0000156744.44218.74
Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ. The association between midlife blood pressure levels and late-life cognitive function: the Honolulu-Asia Aging Study. JAMA. 1995;274:1846-1851. PMID:7500533.
Kilander L, Nyman H, Boberg M, Lithell H. The association between low diastolic blood pressure in middle age and cognitive function in old age: a population-based study. Age Ageing. 2000;29:243-248.
Debette S, Seshadri S, Beiser A, Au R, Himali JJ, Palumbo C, Wolf PA, DeCarli C. Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. Neurology. 2011;77:461-468. https://doi.org/10.1212/WNL.0b013e318227b227
Gottesman RF, Schneider AL, Albert M, Alonso A, Bandeen-Roche K, Coker L, Coresh J, Knopman D, Power MC, Rawlings A, Sharrett AR, Wruck LM, Mosley TH. Midlife hypertension and 20-year cognitive change: the Atherosclerosis Risk in Communities neurocognitive study. JAMA Neurol. 2014;71:1218-1227. https://doi.org/10.1001/jamaneurol.2014.1646
Parfenov VA, Starchina YuA. Cognitive impairment in patients with hypertension and their treatment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2011;3(1):27-33. (In Russ.)
Ostroumova TM, Parfenov VA, Ostroumova OD. Hypertension and cognitive impairment: the standpoint of evidence-based medicine. Nevrologiya, Neiropsikhiatriya, Psikhosomatika. 2017;9(4):70-76. (In Russ.) https://doi.org/10.14412/2074-2711-2017-4-70-76
Yakhno NN. Cognitive impairments in neurological clinic. Nevrologicheskii Zhurnal. 2006;11(suppl 1):4-12. (In Russ.)
Marpillat NL, Macquin-Mavier I, Tropeano A-I, Bachoud-Levi A-C, Maison P. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta-analysis. Journal of Hypertension. 2013;31(6):1073-1082. https://doi.org/10.1097/HJH.0b013e3283603f53
Chazov EI, Oganov RG, Pogosova GV, Shal’nova SA, Romasenko LV, Deev AD. Clinical and epidemiological program of studying depression in cardiac practice in patients with arterial hypertension and coronary heart disease (COORDINATE): the first results of a multicenter study. Kardiologiya. 2007;47(3):28-37. (In Russ.)
Pogosova GV, Romasenko LV. Kliniko-ehpidemiologicheskie harakteristiki pacientov pozhilogo vozrasta, stradayushchih serdechno-sosudistymi zabolevaniyami, komorbidnymi s depressivnymi rasstrojstvami (po rezul’tatam mnogocentrovogo prospektivnogo issledovaniya KOORDINATA). Terapevticheskij Arhiv. 2007;10:79-82. (In Russ.)
Medvedeva CO, Kolbasnikov CV. The severity of anxiety-depressive disorders and their correlation with cerebral and hemodynamic disorders in patients with arterial hypertension in the practice of a general practitioner. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(12):109-111. (In Russ.) https://doi.org/10.17116/jnevro2016116121109-111
Kubzansky LD, Kawachi I. Going to the heart of the matter: do negative emotions cause coronary heart disease? J Psychosomatic Research. 2000;48:323-337. https://doi.org/10.1016/S0022-3999(99)00091-4
Johansen A, Holmen J, Stewart R, Bjerkeset O. Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. The HUNT study, Norway. Eur J Epidemiol. 2011;27(1):63-72. https://doi.org/10.1007/s10654-011-9641-y
Shtarik SYu, Petrova MM, Garganeeva NP. Some aspects of the comorbidity of anxiety-depressive disorders and arterial hypertension. Sibirskij Medicinskij Zhurnal. 2009;24(4):46-48. (In Russ.)
Volel’ BA, Ternovaya ES, Ermusheva AA, Syrkina EA, Ardzinba IB. Personality disorder and cardiovascular diseases (on the model of arterial hypertension and ischemic heart disease). Psihicheskie Rasstrojstva v Obshchej Medicine. 2014;1:4-13. (In Russ.)
Hocaoglu C, Yeloglu CH, Polat S. Cardiac Diseases and Anxiety Disorders. INTECH Open Access Publisher; 2011.
Kong D, Gao H, Lu Y, Qi XW, Ma LL, Kong XQ, Yao DK, Wang LX. Anxiety disorders are associated with increased plasma adrenomedullin level and left ventricular hypertrophy in patients with hypertension. Clinical and Experimental Hypertension. 2013;36(1):27-31. https://doi.org/10.3109/10641963.2013.783049
Yudina NV, Ishutina NP, Raeva TV. Mental disorders in the initial stages of essential arterial hypertension. Meditsinskaya Nauka i Obrazovanie Urala. 2009;1:70-73. (In Russ.)
Skibickij VV, Skibickij AV, Fendrikova AV. Optimization of the Treatment of Uncontrolled Hypertension in Patients With Anxiety and Depressive Disorders. Kardiologiya. 2015;55(12):25-30. (In Russ.) https://doi.org/10.18565/cardio.2015.12.25-30
Duma SN. Evaluation of the clinical efficacy of neuroprotectors affecting the gamma-aminobutyric acid system in the treatment of cognitive disorders in patients with discirculatory encephalopathy of stages I—II. Farmateka. 2010;15:96-100. (In Russ.)
Kanaeva LS, Vazagaeva TI, Yastrebova VV. The use of the Pantogam drug in patients with asthenic disorders is promising. Psihiatriya i Psihofarmakoterapiya. 2009;11(6):34-39. (In Russ.)
Kamchatnov PR, Mihajlova NA, Morozova YuA. The use of rac-gopantenic acid in the treatment of patients with combined somatic and neurological pathology with moderately expressed affective disorders. Consilium Medicum. Nevrologiya i Revmatologiya (Prilozhenie). 2016;1:13-19. (In Russ.)
Kamchatnov PR. Chronic disorders of cerebral circulation — the possibilities of metabolic therapy. Russkij Medicinskij Zhurnal. 2008;5:274-276. (In Russ.)
Pantogam i Pantogam aktiv. Klinicheskoe primenenie i fundamental’nye issledovaniia. Sbornik nauchnykh statei. Pod red. V.M. Kopelevicha. Moskva: Triada-farm; 2009. (In Russ.)
Smulevich AB, Volel’ BA, Ternovaya ES, Nikitina YuM. The use of the drug pantogam active (D-, L-gopanthenic acid) in the therapy of cognitive and anxiety disorders in patients with arterial hypertension. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2015;115(12):40-49. (In Russ.) https://doi.org/10.17116/jnevro201511511240-49
Putilina MV. Anxiety disorders in patients with hypertensive encephalopathy. Medicinskij Sovet. 2011;3-4:107-110. (In Russ.)
Medvedev ME, Albantova KA. Pantogam is an active in the treatment of neurotic, stress-related, and somatoform disorders in patients with a cardiac hospital. Consilium Medicum. 2009;2:15-19. (In Russ.)
Konradi AO, Polunicheva EV. Inadequate adherence to the treatment of hypertension: the causes and ways of correction. Arterial’naya Gipertenziya. 2004;10(3):12-15. (In Russ.)